Topic

Feliza Mirasol is the science editor for 

Articles

AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).

AbbVie to Acquire ImmunoGen in Deal Valued at $10.1 Billion

This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.

AbbVie Collaborates with BigHat Biosciences on Next-Gen Therapeutic Antibodies

Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.

Genentech and NVIDIA Form AI Research Collaboration for Drug Discovery and Development

Editor of Pharmaceutical Technology Europe

The largest biotech hub is set to be built in Lithuania by Northway Group.

Lithuania Set to Become Home to Largest Biotech City

Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms.

Hovione Expands Technology Platforms with ExtremoChem Acquisition

Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.

Autifony Signs $770.5 Million License and Collaboration with Jazz Pharmaceuticals

Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.

Novartis and Legend Biotech Sign Exclusive License Agreement for CAR-T Therapies

Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease.

Spark Therapeutics Partners with SpliceBio on a Gene Therapy for Eye Disease

The California Institute for Regenerative Medicine has partnered with Forge Biologics, which will manufacture AAVs to help accelerate gene therapy programs in California.

CIRM Picks Forge Biologics as AAV Manufacturing Partner

Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.

Deals, Development and Manufacturing